Cepheid Receives Average Rating of “Buy” from Brokerages (NASDAQ:CPHD)
Shares of Cepheid (NASDAQ:CPHD) have received a consensus rating of “Buy” from the nineteen ratings firms that are covering the stock, AnalystRatings.NET reports. Seven investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $51.71.
Several analysts have recently commented on the stock. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Cepheid in a research note on Thursday. They now have a $58.00 price target on the stock, down previously from $62.00. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Cepheid in a research note on Wednesday. They set an “outperform” rating on the stock. Finally, analysts at Craig Hallum upgraded shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Monday, June 9th.
In other Cepheid news, EVP Kerry Flom unloaded 1,282 shares of the company’s stock on the open market in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $48.97, for a total transaction of $62,779.54. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Cepheid (NASDAQ:CPHD) opened at 48.40 on Tuesday. Cepheid has a one year low of $30.95 and a one year high of $55.89. The stock has a 50-day moving average of $46.58 and a 200-day moving average of $48.02. The company’s market cap is $3.375 billion.
Cepheid (NASDAQ:CPHD) last released its earnings data on Thursday, April 17th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.17) by $0.16. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $104.90 million. During the same quarter in the prior year, the company posted $0.11 earnings per share. The company’s quarterly revenue was up 16.3% on a year-over-year basis. Analysts expect that Cepheid will post $-0.34 EPS for the current fiscal year.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.